The following primary antibodies were used: SPINK2 (#HPA026813, Atlas Antibodies, Stockholm, Sweden),
SLC7A11 (#12691S, Cell Signaling Technology, Danvers, MA, USA),
ALCAM (#ab109215, Abcam, Boston, WA, USA),
β-Actin (#ab8266, Abcam) and
GAPDH (#ab9485, Abcam).
The following drugs were used:
Dimethyl sulfoxide (DMSO, #D4540, Sigma-Aldrich, Burlington, MA, USA),
Nutlin-3a (#S8059, Selleckchem, Houston, TX, USA),
erastin (#5499, Tocris, Bristol, UK),
Puromycin (#A1113802, ThermoFisher, Waltham, MA, USA) and C
26H
19NO
4 (#OSSK_987997, Princeton Biomolecular Research, Monmouth Junction, NJ, USA). The drugs were used at the concentrations indicated in the main text.
Pitts H.A., Cheng C.K., Cheung J.S., Sun M.K., Yung Y.L., Chan H.Y., Wong R.S., Yip S.F., Lau K.N., Wong W.S., Raghupathy R., Chan N.P, & Ng M.H. (2023). SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response. International Journal of Molecular Sciences, 24(11), 9696.